Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Cardinal Health is a $223B revenue pharmaceutical and medical products distributor operating one of the largest pharmaceutical distribution networks in the U.S., serving 90% of hospitals and 60,000+ pharmacies. The company operates two segments: Pharmaceutical (90%+ of revenue) distributing branded/generic drugs with razor-thin 2-3% gross margins, and Medical (remainder) distributing surgical supplies, gloves, and at-home medical products with higher 15-20% margins but smaller scale.
Cardinal operates a high-volume, low-margin distribution model with 3.7% gross margins and 1.0% operating margins. Profitability depends on operational efficiency, inventory turns (12-15x annually), and scale advantages in logistics. The pharmaceutical segment earns distribution fees from manufacturers (typically $5-15 per prescription) plus spread on generic drugs where Cardinal can negotiate volume discounts. Medical segment generates higher margins (15-20% gross) through private-label Cardinal Health branded products and value-added services. Competitive advantage stems from $10B+ invested infrastructure including 50+ distribution centers with sophisticated cold-chain capabilities, proprietary pharmacy management software, and long-term contracts with major pharmacy chains (CVS, Walgreens) and hospital systems.
Generic drug launch calendar and exclusivity windows - major launches can add $50-150M in annual profit during exclusivity periods
Pharmaceutical pricing dynamics and manufacturer fee negotiations - 50-100bps margin compression/expansion materially impacts $200B+ revenue base
Opioid litigation settlements and reserve adequacy - company faces $6.4B in settlement obligations through 2038
Medical segment growth and Cardinal Health branded product penetration - higher margin business growing mid-single digits
Specialty pharmaceutical growth in oncology and rare disease - 15-20% margins vs. 2-3% in traditional pharma distribution
Hospital utilization trends and elective procedure volumes - drives Medical segment demand for surgical supplies
Amazon Pharmacy and vertical integration by PBMs/payers - Amazon's entry into pharmacy distribution and potential for CVS/Walgreens to self-distribute could disintermediate wholesalers
Continued pharmaceutical margin compression - manufacturer direct-to-pharmacy models and increased generic competition erode distribution economics
Regulatory risk from drug pricing legislation - potential government price controls or importation policies could disrupt distribution economics and fee structures
Oligopoly competition with McKesson and AmerenSourceBergen - three players control 90%+ market share, leading to intense price competition for large customer contracts
Customer consolidation reducing negotiating leverage - mega-mergers among pharmacy chains and hospital systems increase buyer power and pressure distribution fees
Negative equity position (-$19.3 P/B) due to $6.4B opioid litigation settlement obligations and share repurchases - company has structural negative net worth
High leverage with -3.34 Debt/Equity and $15B+ gross debt - refinancing risk if credit markets tighten, though investment-grade rating provides access to capital
Current ratio of 0.91 indicates working capital pressure - business model requires continuous access to short-term financing for inventory
low - Pharmaceutical demand is non-discretionary and driven by demographics, chronic disease prevalence, and prescription volumes rather than GDP. Medical segment has moderate cyclicality tied to elective procedures and hospital capital spending, but represents only 10% of business. Recession may slightly reduce elective surgeries but increase generic drug utilization as patients trade down from branded drugs.
Rising rates create moderate headwind through two channels: (1) $15B+ debt load increases interest expense by $150M per 100bps rate increase, and (2) working capital financing costs rise as company finances 30-60 day inventory and receivables cycles. However, pharmaceutical distribution contracts often include inflation/cost pass-through provisions. Higher rates also compress valuation multiples for low-growth, high-leverage distributors.
Moderate exposure to healthcare provider credit quality. Cardinal extends 30-60 day payment terms to hospital systems and independent pharmacies. Rural hospital closures and independent pharmacy bankruptcies create bad debt risk, though large chain customers (CVS, Walgreens) represent majority of revenue with minimal credit risk. Tightening credit conditions reduce independent pharmacy formation and consolidate market toward large chains.
value - Stock trades at 0.2x sales and 18x EBITDA with 3.6% FCF yield, attracting deep value investors willing to look past negative book value. Recent 74% one-year return suggests momentum investors have entered. Dividend yield around 2% attracts some income investors, though payout constrained by opioid settlement obligations. Not a growth story given -1.9% revenue decline and mature market position.
moderate - Healthcare distribution is defensive with stable demand, but stock experiences volatility around earnings due to generic launch timing, opioid litigation developments, and large customer contract renewals. Beta likely 0.8-1.0 range. Recent 48.7% six-month return shows elevated volatility as market reprices opioid settlement risk and improved generic economics.